Abstract
To the Editor: With interest we read the article by Jia et al1 in which they investigated the CYP2C19 polymorphisms and antiplatelet effects of clopidogrel in acute ischemic stroke in China. They revealed the correlation between CYP2C19 genotype and neurological function of stroke patients. The authors proposed that patients with none had better outcomes than patients with CYP2C19 loss-of-function alleles, as demonstrated by the National Institute of Health Stroke Scale and the modified Rankin scale scores after treatment. As was known, clopidogrel therapy can prevent stroke patients from recurrent ischemic strokes by inhibiting ADP. Recently, nonresponsiveness is widely recognized and is related to raising rates of recurrent ischemic events and all causes of death.2,3 Cayla et …
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
